Living with idiopathic pulmonary fibrosis

Scullion, JE

doi:10.1177/1479972311424176

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 6 A list of members of the IPF Consensus Working Group can be found in the acknowledgements section.…”

confidence: 99%

Pulmonary fibrosis: “idiopathic” is not “cryptogenic”

Cottin

2019

Eur Respir J

View full text Add to dashboard Cite

consultancy, lectures and travel to meetings; grants to his institution from Boehringer Ingelheim and Roche; personal fees from Bayer/MSD and GSK for consultancy; personal fees from Gilead for acting as a member of an adjudication committee; personal fees from @ERSpublications "Cryptogenic" and "idiopathic" have different roots and slightly different meanings, which could reconcile the seemingly opposing views on terminology for idiopathic pulmonary fibrosis

show abstract

confidence: 99%

Pulmonary fibrosis: “idiopathic” is not “cryptogenic”

Cottin

2019

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Knowledge of this distinction might help to reconcile the seemingly opposing views on terminology [1,3] and the use of the word idiopathic in its original sense. In addition, the fact that pulmonary fibrosis is a chronic, progressive and uncontrolled pathogenic process is much better appreciated by patients and relatives than the widely used explanation that idiopathic means that the doctors ignore the cause of this disease, which is a terrible idea for the patient [6].…”

Section: To the Editormentioning

confidence: 99%

Pulmonary fibrosis: “idiopathic” is not “cryptogenic”

et al. 2019

View full text Add to dashboard Cite

show abstract

“…I diopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown etiology. 1 It is characterized by scarring of the lung tissue, which leads to shortness of breath (dyspnea), a dry cough, inspiratory bibasilar crackles, and fatigue. 2 The prognosis for IPF sufferers is poor, with a 5-year mortality rate higher than that of many common cancers.…”

mentioning

confidence: 99%

Relative Binding Affinities of Integrin Antagonists by Equilibrium Dialysis and Liquid Chromatography–Mass Spectrometry

Tipping

Tshuma

Adams

et al. 2014

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

The integrin αvβ6 is a potential target for treatment of idiopathic pulmonary fibrosis (IPF). Equilibrium dialysis (ED) was investigated for its ability to report ligand binding in an αvβ6 inhibitor screening assay. As a preliminary experiment, an established peptidomimetic inhibitor of the integrin was dialyzed against αvβ6, and the fraction bound (f b) and percentage saturation determined by liquid chromatography-mass spectrometry (LC-MS) analysis. Quantitation of the inhibitor in the two chambers of the ED cartridge revealed an uneven distribution in the presence of αvβ6, corresponding to near saturation binding to the protein (93 ± 3%), while the control (without integrin) showed an equal partitioning of the inhibitor on either side of the dialysis membrane. A competitive ED assay with a 12 component mixture of antagonists was conducted, and the results compared with an established cell adhesion assay for quantifying αvβ6 inhibition of individual antagonists. Compounds clustered into three groupings: those with pIC 50 values between ca. 5.0 and 5.5, which possessed ED f b values indistinguishable from the controls, those with pIC 50s of 6.5 ± 0.2, which exhibited detectable integrin binding (f b 13-25%) in the ED assay, and a single compound of pIC 50 7.2 possessing an f b value of 38%. A good correlation between ED-derived f b and pIC 50 was observed despite the two assays utilizing quite different outputs. These results demonstrate that ED with LC-MS detection shows promise as a rapid αvβ6 integrin antagonist screening assay for mixtures of putative ligands.

show abstract

Living with idiopathic pulmonary fibrosis

Cited by 4 publications

References 11 publications

Pulmonary fibrosis: “idiopathic” is not “cryptogenic”

Pulmonary fibrosis: “idiopathic” is not “cryptogenic”

Pulmonary fibrosis: “idiopathic” is not “cryptogenic”

Relative Binding Affinities of Integrin Antagonists by Equilibrium Dialysis and Liquid Chromatography–Mass Spectrometry

Contact Info

Product

Resources

About